Immix Biopharma Statistics
Share Statistics
Immix Biopharma has 27.51M shares outstanding. The number of shares has increased by 39.48% in one year.
| Shares Outstanding | 27.51M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 3.92% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 16.43M |
| Failed to Deliver (FTD) Shares | 934 |
| FTD / Avg. Volume | 0.57% |
Short Selling Information
The latest short interest is 434.94K, so 1.58% of the outstanding shares have been sold short.
| Short Interest | 434.94K |
| Short % of Shares Out | 1.58% |
| Short % of Float | 2.66% |
| Short Ratio (days to cover) | 2.94 |
Valuation Ratios
The PE ratio is -7.78 and the forward PE ratio is -3.13.
| PE Ratio | -7.78 |
| Forward PE | -3.13 |
| PS Ratio | 0 |
| Forward PS | 18.6 |
| PB Ratio | 7.31 |
| P/FCF Ratio | -10.5 |
| PEG Ratio | n/a |
Enterprise Valuation
Immix Biopharma Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 5.32, with a Debt / Equity ratio of 0.
| Current Ratio | 5.32 |
| Quick Ratio | 5.32 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.94% and return on capital (ROIC) is -99.78%.
| Return on Equity (ROE) | -0.94% |
| Return on Assets (ROA) | -0.77% |
| Return on Capital (ROIC) | -99.78% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.10M |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 26.41K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -72.08% in the last 52 weeks. The beta is 0.1, so Immix Biopharma 's price volatility has been higher than the market average.
| Beta | 0.1 |
| 52-Week Price Change | -72.08% |
| 50-Day Moving Average | 1.77 |
| 200-Day Moving Average | 2.14 |
| Relative Strength Index (RSI) | 50.84 |
| Average Volume (20 Days) | 164.93K |
Income Statement
In the last 12 months, Immix Biopharma had revenue of $0 and earned -$15.43M in profits. Earnings per share was $-0.89.
| Revenue | 0 |
| Gross Profit | -5.47K |
| Operating Income | -16.14M |
| Net Income | -15.43M |
| EBITDA | -16.14M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.89 |
Balance Sheet
The company has $17.51M in cash and $0 in debt, giving a net cash position of $17.51M.
| Cash & Cash Equivalents | 17.51M |
| Total Debt | 0 |
| Net Cash | 17.51M |
| Retained Earnings | -53.41M |
| Total Assets | 25.14M |
| Working Capital | 16.19M |
Cash Flow
In the last 12 months, operating cash flow was -$11.37M and capital expenditures -$52.09K, giving a free cash flow of -$11.42M.
| Operating Cash Flow | -11.37M |
| Capital Expenditures | -52.09K |
| Free Cash Flow | -11.42M |
| FCF Per Share | -0.66 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
IMMX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -43.84% |
| FCF Yield | -20.46% |
Analyst Forecast
The average price target for IMMX is $7, which is 244.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 244.8% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -1.51 |
| Piotroski F-Score | 2 |